Gubra, Sanofi in peptide deal
Gubra ApS (Horsholm, Denmark) partnered with Sanofi (Euronext:SAN; NYSE:SNY) to discover and develop peptide-based drugs for diabetes and obesity. Gubra said the deal builds on an existing research consortium between the biotech, Gentofte Hospital (Hellerup, Denmark) and the University of Copenhagen (Copenhagen, Denmark) for drug discovery focusing on gut peptides that is partially funded by the Danish National Advanced Technology Foundation. Gubra said it and Sanofi will jointly select targets and "most likely" conduct initial screening of peptides against these targets together. The pharma, which could not be reached for details, will be responsible for clinical development and commercialization of any resulting peptides. Sanofi will provide Gubra with undisclosed research funding, and Gubra and its research partners are eligible for undisclosed development, regulatory and commercial milestones as well as royalties. ...